Biotech '24: Oncology (view performance)

The oncology biotech sector is experiencing selective but cautious hiring in 2026, with a focus on roles critical for advancing drug candidates through trials, regulatory processes, and manufacturing. High-performing operators are prioritizing talent in clinical operations, regulatory affairs, and manufacturing, especially as programs move into later development stages. Hiring in early research and discovery remains flat unless new funding rounds are secured. There's a notable increase in demand for specialist roles, including senior regulatory affairs professionals, AI-aware experts, and leaders in cell and gene therapy Chemistry, Manufacturing, and Controls (CMC). Cross-functional capabilities are highly valued, and the integration of AI in R&D is driving demand for clinical data scientists. The expansion of oncology pipelines is also leading to growth in Medical Affairs and Medical Science Liaison (MSL) teams. A strengthening theme would be indicated by sustained growth in clinical development and manufacturing roles, coupled with increased hiring in early-stage research following successful funding rounds. Deterioration would be signaled by widespread hiring freezes, significant layoffs beyond specific restructurings, or a sharp decline in demand for specialized roles critical to drug development and commercialization.

Several second-order trends are shaping the Biotech '24: Oncology theme. The integration of **Artificial Intelligence (AI) in oncology drug discovery and development** is rapidly accelerating, optimizing drug efficacy, minimizing toxicity, and enhancing clinical trial efficiency through intelligent patient stratification and adaptive protocols. AI is proving instrumental in molecular modeling, identifying novel compounds, and improving success rates in early-phase clinical trials. Another significant trend is the **unprecedented wave of oncology-focused Mergers & Acquisitions (M&A), licensing agreements, and strategic partnerships** observed in the first half of 2026. This activity is largely driven by the approaching patent cliff for major drugs and the imperative for large pharmaceutical companies to replenish their pipelines. The focus of these deals is increasingly on **next-generation therapeutic modalities**, including Antibody-Drug Conjugates (ADCs), bispecific antibodies, radioligand therapies, and advanced cell therapies like CAR T-cells, with a particular emphasis on expanding their application to solid tumors. Furthermore, **precision oncology continues its expansion**, driven by technological advancements and the demand for diagnostics that provide effective clinical results and minimize side effects. This includes a shift towards biomarker-driven and tissue-agnostic approaches to cancer care. Finally, there's a growing emphasis on **treating cancers at earlier stages** to improve patient outcomes, reduce recurrence risk, and enhance survival rates.